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http://dx.doi.org/10.1016/j.hkjn.201Summary Induction of epithelial-to-mesenchymal transition (EMT) in mesothelial cells dur-
ing peritoneal dialysis (PD) and peritonitis is an orchestrated process characterized by the loss
of cellecell contact, reorganization of the actin cytoskeleton, basement membrane degrada-
tion, and acquisition of a migratory and invasive phenotype. EMT contributes to peritoneal
fibrosis, which can lead to the failure of PD as a treatment modality for patients with end-
stage renal disease. Decorin is a dermatan sulfate proteoglycan that possesses antifibrotic
properties and has been shown to suppress tissue fibrosis. This review will discuss changes
observed in the mesothelium during PD, induction of EMT and peritoneal fibrosis, and the po-
tential beneficial effect of decorin in the intervention of peritoneal fibrosis.
摘要 腹膜透析本身和腹膜炎均可導致腹膜組織中間皮細胞發生上皮-間葉轉化（epithelial-to-
mesenchymal transition，EMT），這個過程表現為細胞間連接受損、骨架重排以及基底膜降
解，進而細胞呈現遊走性和侵襲性等特徵。間皮細胞EMT可引發腹膜纖維化，後者是腹膜透析患
者技術失敗的常見原因。核心蛋白多醣（decorin）是一種硫酸皮膚素類蛋白多醣，既往研究提
示其有抗纖維化作用。本綜述將闡述腹膜透析過程中間皮細胞EMT以及腹膜纖維化的形態特徵及
發生機制，並討論核心蛋白多醣在緩解腹膜纖維化中的可能作用。Introduction
Peritoneal dialysis (PD) has been used successfully as a first-
line renal replacement therapy for over 30 years and is
currently used by approximately 11% of the total global
dialysis population.1 The success of PD is reliant on theof Medicine, The University
ong.
. Yung).
g Kong Society of Nephrology Ltd
3.09.002structural and functional integrity of the peritoneal mem-
brane. Compelling evidence suggests that long-term use of
conventional glucose-based PD fluids is associated with
detrimental changes in the structure of the peritoneal
membrane, which include epithelial-to-mesenchymal
transition (EMT) in mesothelial cells, mesothelial cell
denudation, reduplication of the basal lamina, thickening
of the submesothelium, subendothelial hyalinization, and
narrowing or obliteration of the vascular lumen, leading to
technique failure and unfavorable clinical outcome.2e5 To. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1 Inducers of EMT and matrix protein synthesis in
mesothelial cells.
Inducers of EMT/fibrogenesis
In vitro studies GDP16e19
TGF-b120,21
IL-1b22
HGF23
CTGF24,25
MCP-126
Twist27
Hyaluronan28
Angiotensin II29e31
Fibronectin32
56 S. Yung et al.limit the detrimental changes to the peritoneal membrane,
an understanding of the mechanisms that promote perito-
neal injury is essential before researchers are able to
devise novel therapeutic strategies to preserve the
longevity of the peritoneal membrane. Recent studies have
demonstrated that decorin expression within the peritoneal
membrane is reduced markedly in PD patients compared to
healthy individuals,6 and this raises the question of whether
decorin plays an important role in peritoneal function. This
review will discuss the mechanisms of EMT and fibrogenesis
in mesothelial cells and the putative role of decorin in
these processes. The roles of other antifibrotic molecules
such as BMP-7 and pharmacological agents have been
described elsewhere.7e9Fibrin33
AGE34
RAGE16
In vivo studies GDP19
TGF-b135
PDGF-B36
VEGF37,38
TNF-a39
IL-1b39
MCP-126
RAGE40,41
Salt intake42
AGE Z advanced glycation end product; CTGF Z connective
tissue growth factor; GDP Z glucose degradation product;
EMTZ epithelial-to-mesenchymal transition; HGFZ hepatocyte
growth factor; IL-1bZ interleukin-1b; MCP-1Z monocyte che-
moattractant protein-1; PDGFZ platelet-derived growth factor;
RAGE Z receptor for advanced glycation endproducts; TGF-
b1 Z transforming growth factor-b1; TNF-a Z tumor necrosis
factor-a; VEGFZ vascular endothelial growth factor.Phenotypic changes in mesothelial cells during
PD
Mesothelial cells are specialized epithelial cells that line
the peritoneal cavity.10e13 They possess a characteristic
polygonal, cobblestone appearance and reside on a base-
ment membrane. These cells are connected by intercellular
junctions, which contribute to the establishment and
maintenance of a continuous, polarized mesothelial
monolayer.10,13 A reduction in the expression of intercel-
lular junctions results in the collapse of cellecell commu-
nication and cellematrix interaction, resulting in the
denudation of the mesothelium, a process often observed
in PD patients.2 What happens to mesothelial cells once
they detach from the mesothelium? A proportion of these
cells, if viable, may support mesothelial restoration or
dedifferentiate, i.e., undergo EMT.14,15 Cells with mesen-
chymal properties have been isolated from PD effluent, but
these cells are unlikely to be peritoneal fibroblasts because
the latter are embedded sparsely within the sub-
mesothelium.15 These cells are likely to originate, at least
in part, from mesothelial cells.
EMT abolishes cellecell contacts in epithelial cells,
reshaping them into elongated fibroblastic cells with
invasive properties that permit them to migrate into the
underlying substratum. The loss of epithelial characteris-
tics and the acquisition of a migratory phenotype under-
score the plasticity property of mesothelial cells. EMT in
mesothelial cells can be initiated by uremia, glucose
degradation products, advanced glycation end products,
profibrotic growth factors, proinflammatory cytokines,
proteases, and oxidative stress (Table 1).16e42 Elevated
glucose concentrations in conventional PD fluids induce
transforming growth factor-b1 (TGF-b1) bioactivation, a
key inducer of EMT and matrix protein production in
mesothelial and other epithelial cells, and its secretion is
induced by prior activation of the protein kinase C
signaling pathway.43,44 Binding of TGF-b1 to its type I cell
surface receptor triggers Smad-dependent and Smad-
independent signaling pathways, which decrease the
expression of the epithelial markers E-cadherin, zonula
occludens, and claudin, mediated, in part, through EMT-
activating transcription factors such as Snail and Twist.
This is followed by the reorganization of the actin cyto-
skeleton with a loss of cytokeratin filaments and the
acquisition of mesenchymal markers such as vimentin, b-catenin, a-smooth muscle actin, and interstitial collagens
(collagen types I and III; Table 2).45,46 TGF-b1 also sup-
presses the synthesis of matrix-degrading proteases and
increases the synthesis of their inhibitors.9 Although a-
smooth muscle actin is commonly used as a biomarker of
EMT, it is noteworthy that a-smooth muscle actin expres-
sion is not a specific marker for fibroblasts and is not
present in newly transitioning cells.47 Independent re-
searchers have suggested that fibroblast-specific protein-1
(FSP-1) may be a more appropriate marker for EMT, but its
specificity for EMT is debatable because experimental
studies of renal injury have demonstrated that FSP-1 is
detected in leukocytes, but not in myofibroblasts or
collagen-synthesizing cells.48 FSP-1-positive cells have
been identified in the peritoneum of mice following the
overexpression of TGF-b1 and have been suggested to be
derived from mesothelial, endothelial, and bone marrow-
derived cells.49 Epithelial cells that have transitioned to
mesenchymal cells secrete elevated levels of proin-
flammatory cytokines, which further contribute to EMT
and exacerbate extracellular matrix synthesis and
angiogenesis.
Due to a lack of suitable technology, real-time transition
of mesothelial cells into myofibroblasts and their migration
Table 2 Changes in EMT and fibrotic markers in mesothelial cells that have undergone phenotypic changes during PD.
Protein Polygonal mesothelial cells Mesothelial cells that have undergone EMT
E-cadherin Highly expressed Decreased expression
N-cadherin Not expressed Expressed
Tight junctions (e.g., ZO-1) Highly expressed Decreased expression
b-Catenin Weakly expressed Expressed
Snail Not expressed Expressed
Twist Weakly expressed Expressed
a-Smooth muscle actin Weakly expressed Expressed
Cytokeratins Highly expressed Decreased expression
Vimentin Weakly expressed Expressed
CA125 Highly secreted Decreased secretion
TGF-b1 Constitutive secretion Increased secretion
VEGF Constitutive secretion Increased secretion
IL-8 Constitutive secretion Increased secretion
Fibronectin Constitutive expression Expressed
Collagen type I Not expressed Expressed
Collagen type III Not expressed Expressed
Collagen type IV Constitutive expression Expressed
Decorin Highly secreted Decreased secretion
CA125 Z cancer antigen 125; EMT Z epithelial-to-mesenchymal transition; IL-8 Z interleukin-8; PD Z peritoneal dialysis; TGF-
b1 Z transforming growth factor-b1; VEGF Z vascular endothelial growth factor; ZO-1 Z zonula occludens-1.
PD and decorin 57into the submesothelium cannot be confirmed in the clin-
ical setting. Rather, researchers can rely only on “snap-
shots” of this process in in vitro and animal studies that
rely predominantly on the detection of EMT markers in
mesothelial cells at a given time. The contribution of EMT
in peritoneal fibrosis in the clinical setting is therefore
open to interpretation. Changes in mesothelial phenotype
and expression of EMT markers are dependent on experi-
mental conditions. In an animal model of PD, Cho et al50
observed differences in the expression of EMT markers in
mesothelial cells present in the peritoneal membrane
(in vivo) and those isolated from peritoneal effluent
(ex vivo). This is not unexpected because mesothelial cells
programmed to detach from the peritoneal membrane may
express distinct markers compared to cells that remain
attached to the peritoneum. It is also noteworthy that
ex vivo studies in which mesothelial cells are removed from
an unfavorable, bioincompatible environment and cultured
in more physiological culture medium do not reflect the
in vivo state.Peritoneal fibrosis and structural changes
within the peritoneal membrane
Approximately 50% and 80% of PD patients develop perito-
neal fibrosis within 1 year and 2 years, respectively, after
entering the PD program.51e53 Peritoneal fibrosis is a mal-
adaptive repair process whereby chronic inflammation and
persistent irritants present in PD fluid sustain the produc-
tion of growth factors, cytokines, and matrix metal-
loproteinases, and, together with the recruitment of
myofibroblasts, result in the progressive accumulation of
matrix proteins, leading to the destruction of the perito-
neal membrane architecture. The repair process can be
divided into two distinct phases: a regenerative phase and afibrosis phase. In the former phase, injured cells are
replaced by viable cells of the same kind with no evidence
of lasting damage, whereas in the latter phase, normal
tissue is replaced with connective tissue resulting in
extensive remodeling of the extracellular matrix and for-
mation of a permanent scar.54 Fibrosis does not occur
alone, but is often accompanied by angiogenesis and
vascular remodeling. In this respect, vascular and intersti-
tial changes within the peritoneum become prominent with
progressive use of PD and highlight a temporal relationship
between peritoneal fibrosis, vasculopathy, and time on PD.2
Mesothelial denudation is invariably observed in PD pa-
tients, which is associated with a thickening of the sub-
mesothelium and vasculopathy.2
Mesothelial cells that have undergone EMT are highly
fibrogenic and contribute to peritoneal fibrosis. It is not
surprising that factors that induce EMT also induce perito-
neal fibrosis. The presence of interstitial collagens is
indicative of tissue fibrosis and are present within the
submesothelium in patients and animals on long-term
PD.2,5,35,55 Transient overexpression of TGF-b1 using
adenovirus-mediated gene transfer of active TGF-b1 into
the peritoneum of rodents results in submesothelial thick-
ening and increased collagen deposition and peritoneal
vascularization.35,56 Although much attention has been
focused on the role of mesothelial cells in fibrotic processes
within the peritoneum, peritoneal fibroblasts also play a
contributing role through lysophosphatidic acid-1 and con-
nective tissue growth factor, and selective depletion of fi-
broblasts can decrease peritoneal fibrosis and
angiogenesis.57,58
Peritoneal inflammation may precede fibrosis, although
experimental models of fibrogenesis suggest that inflam-
mation does not always drive fibrosis. This may in part
explain the ineffectiveness of anti-inflammatory mediators
in the treatment of fibrotic diseases and the need to
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58 S. Yung et al.identify novel antifibrotic therapies.54 Whether advanced
fibrosis in any given tissue can be reversed to a level where
normal tissue architecture and subsequent function are
restored remains controversial.
Long-term use of PD is also a major risk factor for the
development of encapsulating peritoneal sclerosis (EPS), a
rare, life-threatening condition characterized by peritoneal
membrane thickening resulting in bowel encapsulation and
restriction of bowel movement.59,60 It is currently unclear
whether peritoneal fibrosis and EPS are distinct patholog-
ical entities or form part of a measure of severity of the
same disease process. PD takes place predominantly across
the parietal peritoneal membrane, and thus structural
changes are more prominent in this region of the peritoneal
membrane compared to the corresponding visceral perito-
neal membrane.3,61 EPS occurs exclusively in the visceral
peritoneal membrane; this would suggest that distinct
pathogenetic mechanisms are involved.52,62 The etiology
and pathophysiology of EPS fall outside the scope of this
review and have been discussed elsewhere.60,63TGF-β1 deposited 
into the matrix
Decreases collagen 
fibrillogenesis
Figure 1 Modulation of TGF-b1 bioactivity by decorin in the
peritoneum. Elevated glucose concentrations in conventional
PD solutions induce TGF-b1 secretion in resident and infil-
trating peritoneal cells, which contributes to EMT and perito-
neal fibrosis. Decorin is secreted abundantly by mesothelial
cells, and can bind and neutralize the bioactivity of TGF-b1
through its core protein, preventing it from binding to its cell
surface receptor and sequestering it in the extracellular milieu
which acts as a reservoir for the growth factor. Decorine
TGF-b1 interactions will therefore suppress EMT and peritoneal
fibrosis. When TGF-b1 is required for peritoneal homeostasis,
wound healing, or regulation of peritoneal inflammation,
decorin dissociates from the growth factor, which will then be
presented back to the cells. EMTZ epithelial-to-mesenchymal
transition; PD Z peritoneal dialysis; TGF-b1 Z transforming
growth factor-b1.Decorin and the peritoneal membrane
Using cationic tracers such as ruthenium red, anionic sites
are found within the mesothelial glycocalyx and sub-
endothelium, and along the basement membrane of the
peritoneal membrane.64 The density distribution of these
anionic sites present in the basement membrane is
markedly reduced in animal models of acute inflammation
resulting from septic peritonitis and is accompanied by an
increased transperitoneal passage of proteins.65 Although
the nature of these anionic sites was not further investi-
gated, decorin may possibly contribute to the anionic
staining. In line with this hypothesis, Osada et al6 observed
that decorin expression was constitutively expressed
within the peritoneal submesothelium in normal in-
dividuals but decreased in PD patients with increasing time
on PD, and this reduction was further aggravated with
peritonitis.
Decorin is a dermatan sulfate proteoglycan that belongs
to the small leucine-rich proteoglycan family and plays
important roles in the regulation of extracellular matrix
assembly, cell adhesion, proliferation, and apoptosis
through its interaction with various matrix proteins such as
collagen, fibronectin, thrombospondin-1, and tenascin-
X.66e74 It is composed of an N-terminal region where the
dermatan sulfate glycosaminoglycan chain is located, a
central region comprising 12 leucine-rich repeats that are
the primary sites for protein interactions, and a cysteine-
rich C terminal. Decorin plays a critical role in collagen
fibrillogenesis,66,75e77 and decorin deficiency has been
shown to compromise the healing processes, as observed in
the case of skin healing.78 Although the antifibrotic prop-
erty of decorin in renal diseases has been studied exten-
sively,79,80 studies have also shown that decorin can
suppress cell proliferation under pathological conditions
and inhibit angiogenesis during tumorigenesis.81
Decorin has also beendescribed as a “ligand-trap protein”
in which trap proteins are either attached to the cell mem-
brane or circulate in the interstitial space where they act as
accessory molecules that regulate the binding of proteins totheir specific receptors.82 Decorin can modulate TGF-b1
bioactivity andbioavailability bybinding to the growth factor
through its core protein.83 This interaction prevents TGF-b1
from interactingwith its cell surface receptor and sequesters
it in the extracellularmatrix where it serves as a reservoir for
TGF-b1. This growth factor is presented back to the cells
when TGF-b1 levels are reduced (Fig. 1). Decorin is themajor
proteoglycan synthesized and secreted by mesothelial cells,
and is detected in PD effluent.84,85 The ability of mesothelial
cells to synthesize abundant decorin may be an adaptive
mechanism that prevents peritoneal membrane thickening
or adhesion formation consequent to local release of proin-
flammatory and profibrotic mediators during chemical,
bacterial, or surgical injury to the peritoneum. We have
recently demonstrated that decorin can abrogate pheno-
typic changes inmesothelial cells following exposure to TGF-
b1 or PD effluent, and this is accompanied by a decrease in
TGF-b1-mediated induction of a-smooth muscle actin and
fibronectin synthesis (Yung et al, unpublished results).
Decorin is secreted into the peritoneal cavity by mesothelial
cells, plausibly suggesting that it is removed from the peri-
toneal cavity with each exchange of PD solution, and the loss
PD and decorin 59of a natural TGF-b1 antagonist may be a causative mecha-
nism for EMT and progressive peritoneal fibrosis during long-
termPD. It is also conceivable that as glucose-based PDfluids
are detrimental to mesothelial cell function, synthesis of
decorin is also compromised, which may explain its reduced
expression in peritoneal specimens obtained from PD pa-
tients.6 In keeping with the antifibrotic property of decorin,
Margetts et al86 demonstrated that adenovirus-mediated
gene transfer of decorin in a rat model of PD decreased
peritoneal fibrosis significantly, possibly through neutrali-
zation of TGF-b1 activity, but had no effect on peritoneal
vascularization or ultrafiltration. Although inhibition of TGF-
b1 activity is well tolerated in experimental studies,49 one
must be mindful of the importance of this growth factor in
physiological functions and that TGF-b1 knockout is lethal.
Whether results obtained from animal studies can be trans-
lated in the clinical setting remains to be fully elucidated.
Conclusion
Animal and in vitro studies have demonstrated convincingly
that bioincompatible PD fluids and inflammatory processes
can induce EMT and fibrogenesis in mesothelial cells, which
significantly impact on the structural and functional integ-
rity of the peritoneal membrane. Since obtaining longitu-
dinal peritoneal biopsies from PD patients to monitor
progressive changes in the peritoneum with time on PD is
not feasible, ex vivo studies have provided researchers with
an important source of resident peritoneal cells. Whether
mesothelial cells that have detached from the peritoneal
membrane truly represent cells that are still attached is
open to debate.
Experimental models of PD and peritoneal injury that
investigate the underlying mechanisms of EMT and fibro-
genesis offer researchers an invaluable resource to study
changes within the peritoneum with time and assess novel
therapeutic agents; however, understanding the limitations
of animal studies is important, because structural changes
observed in the clinical setting may not always be repro-
duced in experimental studies. Notwithstanding these lim-
itations, substantial progress has been made in the field of
EMT that allows researchers to understand how phenotypic
changes in mesothelial cells can contribute to peritoneal
fibrosis. The next step is to confirm that such changes can
be detected in the clinical setting.
Decorin plays a critical role in regulating renal fibrosis,
and experimental studies have shown similar results in TGF-
b1-mediated peritoneal fibrosis. Further studies are war-
ranted to determine the mechanisms through which decorin
exerts its antifibrotic effect and whether it can induce
mesenchymal-to-epithelial transition and reverse perito-
neal fibrosis.
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